Journal club kit · week of 13 November 2026
Resistance exercise reduced lean mass loss in adults on tirzepatide in a 40-week trial
Incretin-based obesity treatment lowers fat mass, but it also lowers lean soft tissue mass, and this may weaken skeletal muscle function. This randomised trial in 120 adults on tirzepatide tested whether thrice-weekly resistance exercise for 40 weeks protects lean mass and strength. It gives a concrete basis to discuss how exercise fits into obesity care alongside drug treatment.
Paper: Resistance exercise to attenuate lean mass loss during tirzepatide therapy for obesity: a randomized controlled trial.
Green DJ, Haynes A, Underwood DR et al. Nature medicine. 9 November 2026
Discussion questions
What was the study design, and why is it suited to this question?
Model answer
It was a two-arm randomised controlled trial in which all participants received tirzepatide. Randomisation to resistance exercise or usual activities is a strong design for asking whether exercise adds protection for lean mass. The trial is registered (ACTRN12623001236684) and the primary outcomes were clearly stated.
Who was studied, and what were the intervention and comparator?
Model answer
The trial enrolled 120 adults with overweight or obesity, all treated with tirzepatide. They were randomised to thrice-weekly resistance exercise training or to usual activities for 40 weeks. The abstract does not give age, sex or diabetes status, so check the full paper for these.
What were the primary outcomes?
Model answer
The primary outcomes were change in total fat mass and change in total lean soft tissue mass. Appendicular lean soft tissue mass was a related endpoint. Body weight and muscle strength were also reported.
What were the main results?
Model answer
Weight loss (T = -22.61 kg, T+REx = -22.28 kg, P = 0.694) and fat mass loss (T = -17.19 kg, T+REx = -17.98 kg, P = 0.700) were similar. Total lean soft tissue mass fell less with exercise (T = -4.67 kg, T+REx = -3.57 kg, P < 0.001; between-group difference 1.09 kg, 95% CI 0.43-1.75 kg). Strength fell with tirzepatide alone and rose with added exercise, with all P < 0.001.
How applicable are these findings to Indian patients and clinics?
Model answer
The abstract does not say where participants were recruited beyond the Australian New Zealand registry, nor their age, sex, diabetes status or ethnic background. It also does not describe how the exercise programme was delivered, supervised or resourced. Look in the full paper for these details, and for the safety data, before judging fit for Indian patients and settings.
Points to appraise
- Strength: randomisation, a registered trial, clearly stated primary outcomes and high exercise adherence (91%) support the findings.
- Limit: the trial had 120 participants and lasted 40 weeks. Lean soft tissue mass and strength tests are surrogate measures.
- Limit: the abstract does not report falls, fractures, disability or quality of life. It also does not report outcomes after 40 weeks or after tirzepatide is stopped.
- Limit: funding, blinding, drop-outs, participant characteristics and adverse event details are not given in the abstract. Whether the 1.09 kg difference in lean mass is clinically meaningful is not shown, and one trial should be confirmed by others.
Read the full report: Resistance exercise reduced lean mass loss in adults on tirzepatide in a 40-week trial. Residents: get Today’s Rounds by email each morning, free.
Written only from our report and the paper's abstract. Read the full paper before the session. For teaching; not advice for individual patients. Free to use with credit to Diabesity Rounds, diabesityrounds.com.